DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Proof of Concept Study to Investigate the Recurrence of Acne Post Isotretinoin

Information source: Dermatrials Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Acne

Intervention: tretinoin microsphere 0.04% gel (Drug); vehicle gel (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Dermatrials Research

Official(s) and/or principal investigator(s):
Ronald Vender, MD FRCPC, Principal Investigator, Affiliation: Dermatrials Research


The use of topical retinoids is a mainstay and basis of early acne treatment to prevent the progression to inflammatory lesions. Post oral isotretinoin, it is not uncommon for non-inflammatory papules and comedones to recur. However, there has been no formal study to look at the prevention of recurrence of these acne lesions post isotretinoin in a long term basis. This may enhance the therapeutic options for post isotretinoin patients in order to prevent recurrence of their disease. Hypothesis Tretinoin microsphere 0. 04% will prevent recurrence of acne lesions.

Clinical Details

Official title: Double Blinded Vehicle Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Non-inflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients Post Oral Isotretinoin Use

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Primary objectives-to assess the efficacy of Retin A micro 0.04% on the recurrence rate of acne post isotretinoin use compared to vehicle.

Secondary outcome:

The percent change in lesion counts from baseline to week 16 and 24.

Proportion of subjects who have a Subject's Global

Proportion of subjects who have an ISGA score of 0 or 1 at week 16 and 24.

Detailed description: Subjects will be randomized 1: 1 to study product or vehicle. Subjects will be randomly assigned to each group by an unblinded dispenser. The study duration will be 24 weeks with visits at baseline (week 0), week 4, week 8, week 16 and week 24. All study products will be administered once daily for 24 weeks. Subjects will apply a sufficient amount of study product to cover the entire face.


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Male.


Inclusion Criteria: Subjects must fulfill all of the following criteria to be eligible for study admission:

- Males aged between 18 and 45 years old who have successfully completed a treatment of

acne with oral isotretinoin (Min 4 months/Maximum 6 months with an average of 5 months and a total of 120-150mg/kg/course).

- Who can attend scheduled study follow-up visits at the outpatient dermatology clinic.

- Agree to informed consent for participation in a study.

- Agree to comply with the treatment and follow up procedures.

Exclusion Criteria:

- Patients who receive isotretinoin for condition other than acne vulgaris.

- Patients who have been off isotretinoin for less than 30 days or more than 90 days at

the time of enrollment of the study.

- Patients who have used prescription topical acne treatment (tretinoin, benzoyl

peroxide, topical antibiotics or any combination products) between the end of therapy of isotretinoin within 2 weeks of study enrollment or oral antibiotics of any type between the end of therapy of isotretinoin within 4 weeks of study enrollment and throughout the study.

- Patients who have been previously diagnosed with an endocrinological disorder likely

to cause acne such as genital/adrenal hyperplasia, adrenal tumors or any other hypo androgenetic state.

- Patients who are using any of the systemic medications likely to cause or abate acne

such as oral Dilantin or any other epileptic, Finasteride, Spironolactone or Flutamine, testosterone or dietary body-building protein powders.

- Have any nodulo-cystic lesions at baseline.

- Used topical corticosteroids on the face or systemic corticosteroids within the past

4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable.

- Are currently using any medication that in the opinion of the investigator may affect

the action or evaluation of the study product or place the subject at undue risk.

- Used abradants, facials, peels containing glycolic or other acids; masks, washes, or

soaps containing BPO, salicylic acid, or sulfacetamide sodium; non-mild facial cleansers; moisturizers that contain retinol, salicylic acid, or α- or β-hydroxy acids within the past 2 weeks.

- Plan to use medications that are reported to exacerbate acne (e. g., mega-doses of

certain vitamins, such as vitamin D [> 2000 IU per day] and vitamin B12 [> 1 mg/day], haloperidol, halogens [e. g., iodide and bromide], lithium, hydantoin, and phenobarbital), because these may impact efficacy assessments. Subjects who plan to use multivitamins, iron supplements and folate are acceptable.

- Had a facial procedure (such as chemical or laser peel, microdermabrasion, blue light

treatment, etc) performed by an esthetician, beautician, physician, nurse, or other practitioner, within the past 4 weeks or if it is planned to be performed during the conduct of the study.

- Have a known hypersensitivity or have had previous allergic reaction to any of the

active components or excipients of the study product.

- Used any investigational therapy within the past 4 weeks, or currently participating

in another clinical study.

- Are currently abusing drugs or alcohol (drug screening not required).

- Have a significant medical history of being immunocompromised.

- Have other conditions that, in the judgment of the investigator, would put the

subject at unacceptable risk for participation in the study.

- Had any major illness within 30 days before the screening examination.

- Currently are employees of R Vender, an investigator, or contract research

organization (CRO) involved in the study, or an immediate family member (partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.

Locations and Contacts

Dermatrials Research, Hamilton, Ontario L8N 1V6, Canada
Additional Information

Starting date: July 2009
Last updated: February 9, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017